BCRX Earnings Preview

BioCryst swings to $264M profit on $875M revenue surge

The profit swing is real and impressive, but it's heavily asset-sale dependent. For 2026, management expects $635–$660 million in revenue with Orladeyo accounting for $625–$645 million of that range — meaning the core business is essentially flat to slightly declining. This is a one-time earnings beat masking ongoing pressure on the base business. Investors celebrating the profit turnaround need to watch whether the remaining portfolio can sustain momentum without the windfall.

Watch: The 2026 Orladeyo sales guidance is the critical metric. If the ex-US product tracks to the high end of $645 million, the company has revenue cushion; miss and the core business deteriorates faster than this brief suggests. Also track whether management reinstates dividend payments or capital returns now that they've returned to GAAP profitability — a key signal of confidence in sustainable earnings.